M, J. Heald, R. Scratch n9 screen for inhibitors of cell migration. Chem

M, J. Heald, R. Scratch n9 screen for inhibitors of cell migration. Chem Biol 12, 263 (2005). 27. Huang, C., Rajfur, Z., Borchers, C., Schaller, M. D. Jacobson, K. JNK phosphorylates paxillin and regulates cell migration. Nature 424, 21923 (2003). 28. Lampugnani, M. G. Cell migration into a wounded region in vitro. Strategies Mol Biol 96, 1772 (1999). 29. Khan, K. N. M., Paulson, S. K., Verburg, K. M., Lefkowith, J. B. Maziasz, T. J. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 61, 1210 (2002). 30. Guo, X. Nzerue, C. The best way to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 69, 2890, 293, 296 passim (2002). 31. Harirforoosh, S. Jamali, F. Renal adverse effects of nonsteroidal antiinflammatory drugs. Expert Opin Drug Saf 8, 6691 (2009). 32. Alberts, B. et al. Molecular Biology with the Cell. (Garland Science, 2002). 33. Daquinag, A. C., Souza, G. R. Kolonin, M. G. Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles. Tissue Eng Element C Strategies 19, 3364 (2013). 34. Zaman, M. H., Kamm, R. D., Matsudaira, P. Lauffenburger, D. a. Computational model for cell migration in three-dimensional matrices. Biophys J 89, 13897 (2005). 35. Ng, K. W., Leong, D. T. W. Hutmacher, D. W. The challenge to measure cell proliferation in two and three dimensions. Tissue Eng 11, 1821 (2005). 36. Monzack, E. L., Gu, X. Masters, K. S. Efficacy of simvastatin treatment of valvular interstitial cells varies with all the extracellular environment. Arterioscler Thromb Vasc Biol 29, 2463 (2009). 37. Seiler, A. E. M. Spielmann, H. The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc six, 9618 (2011). 38. Friedrich, J., Seidel, C., Ebner, R. Kunz-Schughart, L. A. Spheroid-based drug screen: MyD88 MedChemExpress considerations and sensible method. Nat Protoc 4, 3094 (2009).AcknowledgementsThis study was funded in portion by a National Science Foundation (NSF) Tiny Company Innovation Analysis (SBIR) Award Phase I (0945954) and Phase II (1127551) from NSF IIP Division of Industrial Innovation and Partnerships; along with the State of Texas CDK4 drug Emerging Technology Fund (ETF). The authors thank Timothy Quang, Rice University, Houston, TX, with aid in determining the resolution from the mobile device camera apparatus.Author contributionsD.M.T. and J.C. equally contributed in performing the majority with the experiments and evaluation in Fig. 3, with considerable help from D.S., J.A.G. and W.L.H. within the design and execution of experiments and from S.K.N. and H.T. in data evaluation. M.D., K.P.R., R.M.R., T.C.K. and G.R.S. all contributed towards the assay and experimental style. H.T. prepared the manuscript and figures, with support from T.C.K. and G.R.S.Further informationSupplementary information and facts accompanies this paper at http://nature/ scientificreports Competing economic interests: The University of Texas M. D. Anderson Cancer Center (UTMDACC) and Rice University, in conjunction with their researchers, have filed patents on the technologies and intellectual property reported here. If licensing or commercialization happens, the researchers are entitled to typical royalties. Glauco R. Souza, Robert M. Raphael, T. C. Killian have equity in Nano3D Biosciences, Inc. UTMDACC and Rice University handle the terms of these arrangements in accordance to their established institutional conflict-of-interest policies. The way to cite this article: Timm, D.M. et al. A high-throughput three-dim.